ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

Ascendis Pharma Reports Full Year 2022 Results

16 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma Announces Full Year 2022 Financial Results and Business Update Conference Call on February 16

07 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference

08 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism

04 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:02 By Nasdaq GlobeNewswire

Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism

05 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference

22 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism

14 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years

13 Nov 2022 17:15:00 By Nasdaq GlobeNewswire

Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022

11 Nov 2022 11:10:00 By Nasdaq GlobeNewswire

Ascendis Pharma Reports Third Quarter 2022 Financial Results

02 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

31 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update Conference Call on November 2

26 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT-101, a Phase 1/2 Clinical Trial of TransCon™ TLR7/8 Agonist in Solid Tumors

03 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharma’s TransCon™ PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022

12 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Upcoming Investor Presentations in September

01 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism

31 Aug 2022 07:27:14 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results

10 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10

04 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022

07 Jun 2022 07:00:01 By Nasdaq GlobeNewswire